Li Xia
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Rutgers, The State University of New Jersey (1995); Chongqing University of Posts and Telecommunications (2011); Dalian Ocean University (2007–2008); Jiangnan University (2024); University of North Carolina at Chapel Hill (2002); Nanjing Agricultural University (2014); Harbin University (2013); United States Food and Drug Administration (2025); Central South University (2007–2011); University of Electronic Science and Technology of China (2023); Harbin Medical University (2011); Shanghai Jiao Tong University (2021); Yunnan Agricultural University (2007); Wuhan University of Technology (2021); Chinese Academy of Sciences (2023); Tianjin Foreign Studies University (2012); Qufu Normal University (2011); Peking University (2024); Purdue University West Lafayette (2024); Fudan University (2003–2022); National Health and Family Planning Commission (2021); WuXi AppTec (China) (2024); Tianjin Medical University Cancer Institute and Hospital (2016); Hefei Institutes of Physical Science (2023); Southwest Medical University (2023); China University of Geosciences (2011–2013); Sichuan Agricultural University (2008); Anshan Normal University (2007–2011); Affiliated Hospital of Southwest Medical University (2023); Jiangsu Academy of Agricultural Sciences (2014); First Affiliated Hospital of Sichuan Medical University (2023); Mianyang Central Hospital (2022); Guangdong Special Equipment Inspection and Research Institute (2022); Burke Medical Research Institute (2005–2010); Sichuan Cancer Hospital (2023); Wuxi No.2 People's Hospital (2024); Chinese Academy of Forestry (2020); Research Institute of Forestry (2020); Heze University (2020); Peking University Third Hospital (2024); Shandong Special Equipment Inspection Institute (2022); Segeberger Kliniken (2002); Xijing Hospital (2000); Children's Hospital of Fudan University (2019–2021); China National Rice Research Institute (2014); First Hospital of Xi'an (2014); Guangdong Baiyun University (2012); University of Chinese Academy of Sciences (2007); UNC Lineberger Comprehensive Cancer Center (2002); Chongqing Jiaotong University (2018); Nanjing Medical University (2012); Xinjiang University of Finance and Economics (2007–2012); Shanxi Normal University (2011)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Li Xia's research focuses on understanding the molecular mechanisms underlying various diseases, including cancer, inflammation, and metabolic disorders. Their work investigates how cellular processes like glycolysis and histone modifications contribute to oncogenesis, as demonstrated in studies on pancreatic ductal adenocarcinoma. Other research areas include the role of circular RNAs in inflammatory conditions such as atopic dermatitis and psoriasis, and the regulation of cellular responses to nutrient deprivation through pathways involving mTOR ubiquitination. Xia also explores strategies to enhance cancer therapy, including the use of RORγt agonists to improve anti-PD-1 treatment and the development of targeted radiotracers for improved tumor uptake. Additionally, their work addresses environmental health concerns, examining the impact of nanoplastics on cellular function and gene expression. Li Xia has published 122 papers, with an h-index of 15 and over 5,500 citations, and collaborates with researchers at the National Center for Toxicological Research.
Metrics
- h-index: 16
- Publications: 122
- Citations: 5,659
Selected Publications
-
N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA (2025)
-
Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing (2025)
-
Genotoxicity of nanoparticles evaluated using the <i>in vitro</i> micronucleus assay, a review of recent data <sup>§</sup> (2025)
Collaboration Network
Top Collaborators
- Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing
- N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA
- Genotoxicity of nanoparticles evaluated using the <i>in vitro</i> micronucleus assay, a review of recent data <sup>§</sup>
- Genotoxicity of nanoparticles evaluated using the <i>in vitro</i> micronucleus assay, a review of recent data <sup>§</sup>
- Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing
- Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing
- Germline mutagenicity of molnupiravir and its active form, β-d-N4-hydroxycytidine, in Caenorhabditis elegans evaluated using whole-genome sequencing
- N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA
- N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA
- N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA
- N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA
- N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA
- N-nitroso-ethylisopropylamine mutagenicity in rat liver using the cII transgenic mutation assay and duplex sequencing analysis of genomic DNA
Similar Researchers
Based on overlapping research topics